Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systemic treatments and outcomes in CIC-rearranged Sarcoma: A national multi-centre clinicopathological series and literature review.
Connolly EA, Bhadri VA, Wake J, Ingley KM, Lewin J, Bae S, Wong DD, Long AP, Pryor D, Thompson SR, Strach MC, Grimison PS, Mahar A, Bonar F, Maclean F, Hong A. Connolly EA, et al. Among authors: pryor d. Cancer Med. 2022 Apr;11(8):1805-1816. doi: 10.1002/cam4.4580. Epub 2022 Feb 17. Cancer Med. 2022. PMID: 35178869 Free PMC article. Review.
A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol.
Pryor D, Bressel M, Lawrentschuk N, Tran B, Mooi J, Lewin J, Azad A, Colyer D, Neha N, Shaw M, Chander S, Neeson P, Moon D, Cuff K, Wood S, Murphy DG, Sandhu S, Loi S, Siva S. Pryor D, et al. Contemp Clin Trials Commun. 2021 Jan 6;21:100703. doi: 10.1016/j.conctc.2021.100703. eCollection 2021 Mar. Contemp Clin Trials Commun. 2021. PMID: 33490707 Free PMC article.
Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial.
Siva S, Bressel M, Wood ST, Shaw MG, Loi S, Sandhu SK, Tran B, A Azad A, Lewin JH, Cuff KE, Liu HY, Moon D, Goad J, Wong LM, LimJoon M, Mooi J, Chander S, Murphy DG, Lawrentschuk N, Pryor D. Siva S, et al. Among authors: pryor d. Eur Urol. 2022 Apr;81(4):364-372. doi: 10.1016/j.eururo.2021.12.006. Epub 2021 Dec 23. Eur Urol. 2022. PMID: 34953600 Clinical Trial.
The benefit for radiotherapy at specialised sarcoma centres: A systematic review and clinical practice guidelines from the Australia and New Zealand Sarcoma Association.
Hong AM, Lo H, Lawless A, Zhou D, Bae S, Phillips M, Maclean F, Desai J, Mar J, Lazarakis S, Pryor D, Thompson SR; Australia and New Zealand Sarcoma Association Guidelines Working Party. Hong AM, et al. Among authors: pryor d. Radiother Oncol. 2022 Dec;177:158-162. doi: 10.1016/j.radonc.2022.10.037. Epub 2022 Nov 3. Radiother Oncol. 2022. PMID: 36336110 Review.
TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II.
Siva S, Chesson B, Bressel M, Pryor D, Higgs B, Reynolds HM, Hardcastle N, Montgomery R, Vanneste B, Khoo V, Ruben J, Lau E, Hofman MS, De Abreu Lourenco R, Sridharan S, Brook NR, Martin J, Lawrentschuk N, Kron T, Foroudi F. Siva S, et al. Among authors: pryor d. BMC Cancer. 2018 Oct 23;18(1):1030. doi: 10.1186/s12885-018-4916-2. BMC Cancer. 2018. PMID: 30352550 Free PMC article. Clinical Trial.
Stereotactic body radiotherapy in the management of hepatocellular carcinoma: An Australian multi-institutional patterns of practice review.
Liu HY, Lee YD, Sridharan S, Choong ES, Le H, Wang W, Khor R, Chu J, Oar A, Mott R, Smart J, Jenkins T, Anderson N, Cross S, Loo KF, Wigg A, Stuart K, Pryor D. Liu HY, et al. Among authors: pryor d. J Med Imaging Radiat Oncol. 2021 Jun;65(3):365-373. doi: 10.1111/1754-9485.13184. Epub 2021 Apr 22. J Med Imaging Radiat Oncol. 2021. PMID: 33890425 Review.
286 results